CN105400769B - The hybridoma cell strain of anticoagulin VIII monoclonal antibody - Google Patents
The hybridoma cell strain of anticoagulin VIII monoclonal antibody Download PDFInfo
- Publication number
- CN105400769B CN105400769B CN201510789803.4A CN201510789803A CN105400769B CN 105400769 B CN105400769 B CN 105400769B CN 201510789803 A CN201510789803 A CN 201510789803A CN 105400769 B CN105400769 B CN 105400769B
- Authority
- CN
- China
- Prior art keywords
- cell
- hybridoma
- blood coagulation
- coagulation factor
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 51
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 17
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 17
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 230000003248 secreting effect Effects 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 47
- 239000001963 growth medium Substances 0.000 abstract description 22
- 108010023321 Factor VII Proteins 0.000 abstract description 19
- 239000000427 antigen Substances 0.000 abstract description 17
- 102000036639 antigens Human genes 0.000 abstract description 17
- 108091007433 antigens Proteins 0.000 abstract description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract description 14
- 238000010790 dilution Methods 0.000 abstract description 13
- 239000012895 dilution Substances 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 9
- 201000000050 myeloid neoplasm Diseases 0.000 abstract description 9
- 230000007910 cell fusion Effects 0.000 abstract description 7
- 238000003556 assay Methods 0.000 abstract description 6
- 229940098773 bovine serum albumin Drugs 0.000 abstract description 6
- 238000010367 cloning Methods 0.000 abstract description 5
- 210000004989 spleen cell Anatomy 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 238000000034 method Methods 0.000 description 34
- 239000003431 cross linking reagent Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 21
- 239000007788 liquid Substances 0.000 description 17
- 230000003053 immunization Effects 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- -1 small molecule compound Chemical class 0.000 description 7
- 238000001042 affinity chromatography Methods 0.000 description 6
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 230000001588 bifunctional effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000790917 Dioxys <bee> Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GPNPAMBBKMOQII-UHFFFAOYSA-N (2-fluoro-3-nitrophenyl)-phenylmethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1F GPNPAMBBKMOQII-UHFFFAOYSA-N 0.000 description 1
- VOTJUWBJENROFB-UHFFFAOYSA-N 1-[3-[[3-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VOTJUWBJENROFB-UHFFFAOYSA-N 0.000 description 1
- WQQBUTMELIQJNY-UHFFFAOYSA-N 1-[4-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-2,3-dihydroxy-4-oxobutanoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1CC(S(O)(=O)=O)C(=O)N1OC(=O)C(O)C(O)C(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O WQQBUTMELIQJNY-UHFFFAOYSA-N 0.000 description 1
- KHAWDEWNXJIVCJ-UHFFFAOYSA-N 1-fluoro-4-(4-fluoro-3-nitrophenyl)sulfonyl-2-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 KHAWDEWNXJIVCJ-UHFFFAOYSA-N 0.000 description 1
- HVLGNZWAUGQTTF-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)butanedioic acid;ethane-1,2-diol Chemical compound OCCO.OC(=O)CC(C(O)=O)N1C(=O)CCC1=O.OC(=O)CC(C(O)=O)N1C(=O)CCC1=O HVLGNZWAUGQTTF-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- HJBUBXIDMQBSQW-UHFFFAOYSA-N 4-(4-diazoniophenyl)benzenediazonium Chemical compound C1=CC([N+]#N)=CC=C1C1=CC=C([N+]#N)C=C1 HJBUBXIDMQBSQW-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MOMKPYAIESLQSC-UHFFFAOYSA-N C(CCCC(=O)O)(=O)O.C(CCCCCCC(=O)O)(=O)O.C(CCC(=O)O)(=O)O Chemical compound C(CCCC(=O)O)(=O)O.C(CCCCCCC(=O)O)(=O)O.C(CCC(=O)O)(=O)O MOMKPYAIESLQSC-UHFFFAOYSA-N 0.000 description 1
- DJUKOJWSBZPKGB-UHFFFAOYSA-N C(CCCCCCC(O)=N)(O)=N.C(CCC(=O)O)(=O)O Chemical compound C(CCCCCCC(O)=N)(O)=N.C(CCC(=O)O)(=O)O DJUKOJWSBZPKGB-UHFFFAOYSA-N 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- IWYRWIUNAVNFPE-UHFFFAOYSA-N Glycidaldehyde Chemical compound O=CC1CO1 IWYRWIUNAVNFPE-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 1
- 241000566598 Podomys floridanus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- IYBKWXQWKPSYDT-UHFFFAOYSA-L ethylene glycol disuccinate bis(sulfo-N-succinimidyl) ester sodium salt Chemical compound [Na+].[Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)C(S([O-])(=O)=O)CC1=O IYBKWXQWKPSYDT-UHFFFAOYSA-L 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to the hybridoma cell strains and preparation method thereof of secretion human blood coagulation factor VIII resisting monoclonal antibody.Balb/c mouse is immunized as antigen by the conjugate after using bovine serum albumin(BSA) BSA and human blood coagulation factor VII I to be coupled in the present invention, its spleen cell and SP2/0 myeloma cell is taken to carry out cell fusion, selective culture is carried out with HAT culture medium, using limiting dilution assay by multiple cloning, finally screening obtains the hybridoma cell strain of stably excreting human blood coagulation factor VIII resisting monoclonal antibody.Strain of hybridoma strain prepared in accordance with the present invention is preserved in China typical culture collection center, and deposit number is CCTCC C2015196.
Description
Technical field
The present invention relates to hybridoma cell strains and preparation method thereof, and in particular, to human blood coagulation factor VIII resisting monoclonal
Hybridoma cell strain of antibody and preparation method thereof.
Background technique
Coagulation factor is a kind of key protein ingredient for participating in coagulation process.Its physiological action is, in angiorrbagia
When be activated together with platelet adhesion mend plug blood vessel on leak.This process is referred to as blood coagulation.In haemophiliac
In, 80% patient is hemophilia A, i.e. hemophilia A, such patient mainly lacks the coagulation factor that normal person is possessed
VIII.Hemophilia A is a kind of lifelong disease, can only be by being transfused human blood coagulation at present still without the method for radical cure
VIII substitute products are treated.
Structure is complicated for factor VIII molecule, molecular weight 330kDa, is a kind of biggish plasma protein molecule.Its
Content in blood plasma is only 0.1-0.2 μ g/mL, and half-life period is about 12 hours.Since its extractive technique is extremely difficult, and China exists
Extensive affinity chromatography is technically relatively backward, still asks at present without high-purity blood clotting factors product of affinity chromatography preparation
Generation.Therefore, Factor VIII product wretched insufficiency on domestic market is caused, domestic A type blood friend cannot be sufficiently fed
The case where patient uses, and often will appear off-drug endangers the health and lives safety of domestic patient.
The difficult point of the chromatography technology of plasma protein is the high viscosity of blood plasma and the enormousness of single treatment.For
The separation of the micro plasma protein of blood clotting factors, affinity chromatography are optimal way of purification.Currently, most enterprises in the world, packet
It includes the method that maximum blood product enterprise CSL also uses cold ethanol joint chromatography and carrys out separated plasma albumen.In last century 90
Age, hundred it is special prepared the ultrapure VIII factor and the VII factor using antibody affinity chromatography method, specific activity up to 3000IU/mg,
The general activity rate of recovery is more than 30%.And China prepares the VIII factor then still using the crude acquisition of cryoprecipitate at present, specific activity is more
Lower than 100IU/mg, activity recovery is about 6% or so.
Therefore, in order to increase substantially the separative efficiency of coagulation factor using affinity chromatography, key technology bottleneck is system
Standby effective affinity chromatography antibody.Thus, there is the need to specific coagulation Factor IX monoclonal antibody in this field
It asks.
Summary of the invention
To solve the above-mentioned problems, the present invention provides a kind of hybridization for secreting human blood coagulation factor VIII resisting monoclonal antibody
Tumor cell strain and preparation method thereof.
In the first aspect, the present invention provides a kind of hybridization for preparing secretion human blood coagulation factor VIII resisting monoclonal antibody
The method (being also referred to as " method of the invention " sometimes herein) of tumor cell strain, the described method comprises the following steps:
1) immunizing antigen is prepared: by homotype bifunctional protein crosslinking agent by human blood coagulation factor VII I and bovine serum albumin(BSA)
Coupling, obtains human blood coagulation factor VII I- bovine serum albumin(BSA) conjugate；
2) mouse is immunized: using low dose of long period immunization protocol, utilizing human blood coagulation factor VII I- obtained in step 1)
Bovine serum albumin(BSA) conjugate acting immune antigen, is immunized Balb/c mouse；
3) cell fusion: the spleen for the immune Balb/c mouse that SP2/0 murine myeloma cell and step 2) are obtained is thin
Born of the same parents' fusion carries out selective culture in the RPMI-1640 culture medium containing HAT；
4) the selectivity culture of hybridoma: fused cell is selectively trained in HAT culture medium in step 3)
After supporting, the fused cell of Mouse spleen cells and mouse hybridoma cell SP2/0 is selected；And
5) monoclonal: the hybridoma for being detected as the positive obtained in step 4) is more through limiting dilution assay progress
Secondary monoclonal obtains the hybridoma cell strain of stably excreting human blood coagulation factor VIII resisting monoclonal antibody.
In the second aspect, the present invention provides the hybridoma cell strains of secretion human blood coagulation factor VIII resisting monoclonal antibody
(hereinafter sometimes called " hybridoma cell strain of the invention "), the hybridoma cell strain is to prepare by means of the present invention
's.
In a preferred embodiment, strain of hybridoma strain prepared by the method for the present invention was in 2015
November 6 was preserved in China typical culture collection center, address are as follows: in the preservation of Wuhan City, Hubei Province Wuchang District Wuhan University
The heart, deposit number are CCTCC C2015196, culture title are as follows: hybridoma cell strain F8-M-01.
Specific embodiment
Definition:
" protein-crosslinking agent " is small molecule compound, and molecule both ends respectively have one or more for special base
Group (- NH2,-COOH ,-HS etc.) reactive terminal, can be coupled respectively with the active group in biomolecule, to make this
A little molecules are combined together.Protein-crosslinking agent can be divided into homotype bi-functional cross-linking agent (also referred to as " homologous crosslinking agent "), special-shaped pair
Functional cross-link agent (also referred to as " heterologous crosslinking agent ") and photoactivated cross-linking agent (also referred to as " photoreactivity crosslinking agent ") three classes.
The molecule both ends reactive terminal having the same or priming reaction group of homotype bifunctional protein crosslinking agent.It is common
Homotype bi-functional cross-linking agent be well known in the present art, non-limiting example includes but is not limited to that NHS esters crosslinking agent is all
Such as bis- thiobis (sulfonic acid of n-hydroxysuccinimide (NHS), two thiobis (succinyl phosphorons amino propyl acid ester) (DSP) and 3,3'-
Succinimidyl Propionate) (DTSSP), succinic acid suberic acid diimine (DSS) and butadiene-styrene copolymer (BS),
Two succinimide ester of tartaric acid (DST) and Sulfo-DST, bis- (2- [succinimidyloxycarbonyl oxygen) ethyls) sulfone
(BSOCOES) and sulfo-BSOCOES, ethylene glycol bis- [succinimido succinic acid] (EGS) and sulfo-EGS, succinic acid
Suberic acid glutarate (DSG), N, bis- succinimidyl carbonate of N'- (DSC)；Carbodiimide class such as 1- ethyl -3- [3-
Dimethylaminopropyl] carbodiimide hydrochloride (EDC)；Imido esters crosslinking agent such as dimethyl diiminoester (DMA), diformazan
Base imines ester (DMP), two acid imide ester (DMS) of dimethyl benzene, di-tert-butyl peroxide (DTBP)；Sulfydryl reacts class crosslinking agent
Such as 1,4- bis- (3`- [2`- disulfide group pyridine] propionic acid acylamino-) butane (DPDPB)；The 1,5- bis- fluoro- 2 of difluoro bezene derivative,
4- dinitrobenzene (DFDNB), bis- (the fluoro- 3- nitrobenzophenone of 4-) sulfoxides (DFDNPS) etc.；Photoreactivity crosslinking agent class crosslinking agent is all
Such as double-[β-(azido salicyl amino) ethyl] disulphide (BASED)；Aldehyde crosslinking agent such as formaldehyde, glutaraldehyde
Deng；1,4- butanediol glycidaldehyde of di-epoxide class etc.；Hydrazides crosslinking agent such as adipic dihydrazide, carbohydrazide
Deng；Double derivative species crosslinking agent is by the o- tolidine of diazonium, bis-diazotized benzidine etc.；And double alkyl halides
Deng.
Photoreactivity crosslinking agent is the crosslinking agent with photoreactive group.The priming reaction base of homotype bi-functional cross-linking agent
Group is also possible to photoreactive group.
Type, the reactive group, protein binding group, light work of part homotype bifunctional protein crosslinking agent are listed in table 1
The properties such as the property changed.
Table 1
" antibody " (antibody) refers to that the immune system of body under antigenic stimulus, is increased by bone-marrow-derived lymphocyte or memory cell
Grow the immunoglobulin that the thick liquid cell being divided into is generated, can specifically bind with corresponding antigens.
The present invention provides a kind of preparation sides of hybridoma cell strain for secreting human blood coagulation factor VIII resisting monoclonal antibody
Method.
In one embodiment, the method for the present invention includes the following steps:
1) immunizing antigen is prepared: by homotype bifunctional protein crosslinking agent by human blood coagulation factor VII I and bovine serum albumin(BSA)
(BSA) it is coupled, obtains human blood coagulation factor VII I-BSA conjugate；
2) mouse is immunized: using low dose of long period immunization protocol, utilizing human blood coagulation factor VII I- obtained in step 1)
BSA conjugate acting immune antigen, is immunized Balb/c mouse；
3) cell fusion: the spleen for the immune Balb/c mouse that SP2/0 murine myeloma cell and step 2) are obtained is thin
Born of the same parents' fusion carries out selective culture in 1640 culture mediums containing HAT；
4) the selectivity culture of hybridoma: fused cell is selectively trained in HAT culture medium in step 3)
After supporting, the fused cell of Mouse spleen cells and mouse hybridoma cell SP2/0 is selected；And
5) monoclonal: the hybridoma for being detected as the positive obtained in step 4) is more through limiting dilution assay progress
Secondary monoclonalization obtains the hybridoma cell strain of stably excreting human blood coagulation factor VIII resisting monoclonal antibody.
In the method for the invention, any homotype bifunctional protein crosslinking agent as known in the art can be used, preferably
Carbodiimide albuminoid crosslinking agent, more preferable EDC.
In the present invention, animal immune is using low dose of multiple immunization protocol, conventional with 100~200 μ by taking mouse as an example
The dose immunization of g/ only, is immunized 3~4 times.One specific immunization protocol example is: the female using immunizing antigen to 7 week old
Balb/c mouse is immunized, and by the immunizing dose of 100 μ g/ only, 1:1 is mixed by volume with Freund's complete adjuvant, and emulsification reaches
To Water-In-Oil shape, by the comlete antigen of emulsification, immune mouse is subcutaneously injected in the nape of the neck multiple spot, after 2 weeks, with same antigen and waits bodies
Long-pending incomplete Freund's adjuvant emulsification, 100 μ g/ only carry out booster immunization, and row third time is immune after 2 weeks, and dosage and method are the same as the
Secondary immunity carries out last time to mouse before cell fusion and impacts immune, the immunizing dose intraperitoneal injection of 100 μ g/ only.
In the method for the invention, the method for cell fusion is unrestricted, can using method as known in the art and
Process.
In the method for the invention, the method for antibody test is unrestricted, can use detection side as known in the art
Method, for example, ELISA method can be used.
By means of the invention it is also possible to filter out the hybridoma of secretion human blood coagulation factor VIII resisting monoclonal antibody
Strain.
As example, the hybridoma of secretion human blood coagulation factor VIII resisting monoclonal antibody of the invention is provided below
One exemplary fabrication flow of strain:
1) preparation of immunizing antigen:
It takes 1mg human blood coagulation factor VII I to be dissolved in 0.25mLDMSO solution, EDC is added, is protected from light is aggressively shaken 2 at room temperature
Hour, 4 DEG C reaction overnight, above-mentioned solution is slowly added dropwise in BSA solution, be protected from light at room temperature concussion 2 hours, reaction product in
0.05molL-1It is protected from light dialysis 72 hours in PBS buffer solution, obtains the conjugate of blood coagulation factor VIII Yu carrier protein BSA.
2) mouse immune:
User's blood coagulation factor VIII-BSA conjugate carries out the female Balb/c mouse of 7 week old as immunizing antigen
Immune, by the immunizing dose of 100 μ g/ only, 1:1 is mixed by volume with Freund's complete adjuvant, and emulsification reaches Water-In-Oil shape, will be newborn
The comlete antigen of change, immune Balb/c mouse is subcutaneously injected in the nape of the neck multiple spot, after 2 weeks, with same antigen and isometric Freund
Freund's incomplete adjuvant emulsification, 100 μ g/ only carry out booster immunization, and row third time is immune after 2 weeks, and method is immune with second, in cell
Last time is carried out to mouse before fusion and impacts immune, the immunizing dose intraperitoneal injection of 100 μ g/ only.
3) the selectivity culture of cell fusion and hybridoma:
SP2/0 murine myeloma cell is taken to mix with immune Balb/c Mouse spleen cells in the ratio of 1:5-1:10
Even, 1300rpm is centrifuged 7 minutes, sets the preheating of 40 DEG C of metal baths, is added in 45s with 1mL suction pipe and is preheated to 40 DEG C of 1mL50%
PEG4000, side edged gently vibrate, and 1640 incomplete culture mediums that 30mL is preheated to 37 DEG C are then added in 90s, and room temperature is quiet
It setting 10 minutes, 1000rpm is centrifuged 5 minutes, abandons supernatant, and 1640 culture mediums of the 20mL containing 20% fetal calf serum and HAT are added and are resuspended,
It is dispensed on the culture plate of existing feeder cells, in 5% carbon dioxide incubator culture, after 7 days, observes the growth shape of cell
Condition is swapped out 1/2 culture medium with 1640 culture mediums containing 20% fetal calf serum and HT, after 14 days, use instead 20% fetal calf serum and
HT1640 culture medium culture.
4) hybridoma of screening secretion human blood coagulation factor VIII resisting antibody:
It is 2ug/ml that antibody, which is diluted to protein content, with the carbonate of 0.05M pH9.6 coating buffer, each
Add 50 μ l in the reacting hole of polystyrene board, 4 DEG C overnight.Next day discards solution in hole, washes 3 times with washing buffer, and every time 3
Minute (referred to as washs, similarly hereinafter).Add skimmed milk power (BD company) PBS containing 5% in the reacting hole of each polystyrene board
300 μ l set 37 DEG C and are incubated for 2 hours, are washed out.Add certain diluted 50 μ l of measuring samples in the above-mentioned reacting hole being coated with
In, it sets 37 DEG C and is incubated for 1 hour, be washed out (while doing blank well, negative control hole and Positive control wells).In each reacting hole
In, the 50 μ l of enzyme labelled antibody (by specification is diluted) of diluted is added, 37 DEG C are incubated for 1 hour, are washed out.
The 50 μ l of tmb substrate solution of Extemporaneous is added in each reacting hole, develops the color 15 minutes at 37 DEG C.2M is added in each reacting hole
50 μ l of sulfuric acid terminates reaction.In the result that in white background, directly detects by an unaided eye: color is deeper in reacting hole, and positive degree is got over
By force, negative reaction is colourless or extremely shallow, according to the depth of be in color, is indicated with "+", "-" number.As a kind of alternative judgement
Mode can also be surveyed OD value on ELISA detector, be detected in 450nm and 630 dual wavelengths, after being returned to zero with blank control wells
Each hole OD value is surveyed, it is as positive if more than 2.1 times of defined negative control OD value.
5) monoclonal:
By positive hybridoma through limiting dilution assay carry out multiple monoclonalization obtain the anti-human blood coagulation of stably excreting because
The hybridoma cell strain of sub- VIII monoclonal antibody.
In a preferred embodiment, strain of hybridoma strain prepared by the method for the present invention is named as
F8-M-01, and China typical culture collection center, address are deposited on November 6th, 2015 are as follows: Wuhan City, Hubei Province Wuchang
Wuhan University, area collection, deposit number are CCTCC C2015196.
The preparation method of hybridoma cell strains F8-M-01 the following steps are included:
Human blood coagulation factor VII I (DMSO) solution is prepared, 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide is added
(EDC) it is activated.By above-mentioned solution be slowly added dropwise in bovine serum albumin(BSA) (BSA) solution carry out human blood coagulation factor VII I with
The coupling of BSA, reaction product are dialysed with phosphate buffer (PBS), obtain the idol of human blood coagulation factor VII I Yu carrier protein BSA
Join object.Serum titer is taken to be greater than 1 by immune mouse tail vein blood with enzyme-linked immunosorbent assay detection after four times are immune:
The splenocyte of 10000 mouse is merged with myeloma cell SP2/0；With containing, hypoxanthine (H), aminopterin-induced syndrome (A) and thymus gland are phonetic
Pyridine nucleosides (T) selectivity culture solution (HAT is purchased from SIGMA company) and the RPMI-1640 of 20% fetal calf serum (are purchased from
HYCLONE company) culture solution culture, seven days cells initially form colony after fusion；It is wrapped with human blood coagulation factor VII I antigen
Quilt is screened by enzyme-linked immunosorbent assay (ELISA)；By four time clonings, it is anti-human solidifying finally to obtain one plant of stably excreting
The hybridoma cell strain of blood factor VIII monoclonal antibody, is named as F8-M-01.Using this strain of hybridoma with 1 × 106
A/amount intraperitoneal injection only acquires abdomen in advance with the Balb/c female mice of the 8-10 week old of atoleine sensitization after 10-14 days
Water, by enzyme-linked immunosorbent assay detect ascites be the positive, and by immunoblotting prove its can identify people's blood coagulation because
Sub- VIII.Monoclonal antibody through the measurement hybridoma cell strain F8-M-01 secretion of mouse monoclonal antibody subclass parting kit is sub-
Type is IgM.
Embodiment
1, material and instrument
1.1 cell strains, tissue specimen and animal
A. it myeloma cell (SP2/0): derives from ATCC (American Type Culture collection warehousing).
B.Balb/c mouse: it is purchased from Tsinghua University animal platform.
1.2 main agents
A. Freund's complete adjuvant, freund 's incomplete adjuvant, HAT, HT, TMB, PEG (molecular weight 4000), EDC: are purchased from
Sigma company；
B.HRP marks sheep anti-mouse igg: being purchased from Gibco company；
C.RPMI1640 culture medium: it is purchased from HyClone company；
D. cellulose acetate film (NC): it is purchased from Hybond company；
E. fetal calf serum: it is purchased from PAN company；
F. mouse monoclonal antibody subclass parting kit: purchased from Thermo points of departments；
G. it is coated with buffer: the sodium carbonate of 0.795g and the sodium bicarbonate group of 1.465g being added in every 500ml deionized water
At pH value 9.6.
H. the disodium hydrogen phosphate of 9.2g and the lemon of 2.55g substrate buffer solution: are added in every 500ml deionized water
Acid composition, pH value 5.0.
I.TMB (tetramethyl benzidine) uses liquid: TMB (10mg/5ml dehydrated alcohol) 0.5ml substrate buffer solution (pH5.5)
10ml 30%H2O20.01μl；
J. 7.5% sodium bicarbonate 15ml group incomplete 1640 culture medium: is added in the 1640 culture medium stoste of every 500ml
At.
K. the fetal calf serum composition of 20ml complete 1640 culture medium: is added in every incomplete 1640 culture medium of 80ml.
L. antibody diluent: the BSA composition of 0.1g is added in the PBS of every 100ml.
M. washing buffer: the Tween-20 composition of 0.5ml is added in the PBS of every 100ml.
N.PEG prepares liquid: 7.5% carbonic acid of the DMSO and 0.1ml of 1ml being added in every incomplete 1640 culture medium of 8.9ml
Hydrogen sodium composition.
1.3 key instrument
A. carbon dioxide incubator: Heraeus company；
B. superclean bench: Suzhou cleaning equipment instrument plant；
C. inverted microscope: Leica company；
D.37 a DEG C thermostatted water educates case: Yuyao City east electric instrument factory；
E. 96 hole of Polystyrene plastic plate (ELISA Plate), tissue culture plate (96 holes and 24 holes): NEST company；
F. centrifuge: Eppendorf company
G. pure water meter: Milipore company
H. miniature vertical disk electrophoresis slot: Bio-Rad company
I. microplate reader: TECAN company
2, method
2.1 cell culture: myeloma cell SP2/0 is incubated in complete 1640 culture medium, is placed in the dioxy of 37 DEG C, 5%
Change carbon cell incubator, changes liquid 1 time, pass on 1 time every other day within 3-4 days.
The preparation of 2.2 antigens: taking 1mg human blood coagulation factor VII I to be dissolved in 0.25mL DMSO solution, measures 2mmol EDC
It is added in above-mentioned solution, is protected from light is aggressively shaken 2h at room temperature, 4 DEG C of reactions later are overnight.The coupling of human blood coagulation factor VII I: will be upper
It states solution and is slowly added dropwise that (2mg albumen is dissolved in 1mL 0.1mol L in BSA solution-1In sodium bicarbonate solution), magnetic rotor is added,
It is placed on magnetic force oscillator, is protected from light oscillation 2h at room temperature；Reaction product is in 0.05mol L-1It is protected from light at 4 DEG C in PBS buffer solution
72h is analysed, every 5h replacement dialyzate is primary, obtains the conjugate of human blood coagulation factor VII I Yu carrier protein BSA.
2.3.1 mouse immune
Balb/c mouse (4-8 week old, female) 3 is immunized in antigen after coupling, the specific steps are as follows: a. exempts from for the first time
Epidemic disease: human blood coagulation factor VII I-BSA100 μ g/ only, with 1ml/ only subcutaneous multiple spot after adding isometric Freund's complete adjuvant to mix well
Inject Balb/c mouse, 0.2ml/ point；Interval 2 weeks.
B. be immunized for second: dosage and approach are same as above, and this time add isometric freund 's incomplete adjuvant, are spaced 2 weeks.
C. third time is immune: dosage is same as above, and is this time added isometric freund 's incomplete adjuvant, is taken after 10 days and mouse is immunized
Tail vein (sets 4 DEG C of refrigerator overnights after acquisition, next day stays supernatant spare after ten minutes with 2000 revs/min of centrifugations), passes through
ELISA measures serum titer.
D. the 4th time it is immune: dosage is same as above, and adjuvant is not added, and directly intraperitoneal injection is immunized.
2.3.2ELISA method detection is by immune serum potency process:
A. detection the previous day dilutes antigen human blood coagulation factor VII I to 15 μ g/ml with coating buffer, enzyme linked immunological is added
In adsorption plate, every 100 μ l of hole sets 4 DEG C of refrigerator overnights；
B. next day pours out the liquid in coated enzyme linked plate holes, with washing buffer washing totally 3 times, pats dry every time；
C. it is separately added into that (serum: PBS is respectively 1:100 with the serum to be checked of PBS row gradient dilution；1:1000；1:
2000；1:4000；1:8000；37 are set using the serum of non-immune Balb/c mouse as negative control in 1:16000) 100 hole μ l/
DEG C constant water bath box 1 hour；
D. the liquid in enzyme linked plate holes is poured out, with washing buffer washing totally 3 times, is patted dry every time；
E. sheep anti-mouse igg antibody (with the dilution of antibody diluent row 1:5000) 100 μ l of HRP label are added in every hole, set
37 DEG C constant water bath box 1 hour；
F. the liquid in enzyme linked plate holes is poured out, with washing buffer washing totally 3 times, is patted dry every time；
G. develop the color: being added the tmb substrate solution 50 μ l of Extemporaneous in each reacting hole, 37 DEG C 15 minutes.
H. result judgement: microplate reader detection.
Determine that three immune mouse generate the antibody for human blood coagulation factor VII I by ELISA testing result, takes it
The mouse of middle OD value highest (potency is greater than 10000) carries out subsequent step.
2.3.3 the preparation (fusion the previous day takes Turnover of Mouse Peritoneal Macrophages) of feeder cells:
Using the Balb/c female mice of 7 week old；It draws neck to put to death, is soaked in 75% alcohol and sterilizes 5 minutes, cut with sterile
Knife abdominal cut skin is to expose peritonaeum, and with the incomplete 1640 culture medium of asepsis injector per injection 8ml, repeated flushing is inhaled
Flushing liquor is put into 50ml centrifuge tube and (shares about 40ml) out, is centrifuged 5 minutes with 1300 revs/min；It abandons after supernatant with complete 1640
Precipitating is resuspended in culture solution, and adjustment cell number is 4 × 105A/ml, be added 24 porocyte culture plates, 500 holes μ l/, be put into 37 DEG C,
5% carbon dioxide cell incubator culture.
2.3.4 cell fusion
A. observe myeloma cell SP2/0 state (it is required that best in logarithmic growth phase), by prepared 50%PEG and
The incomplete 1640 culture medium of 20ml is put into 37 DEG C of cell incubator preheatings；It (preparation of 50%PEG: is prepared in fusion the previous day
It is spare that 50% PEG sets 4 DEG C of refrigerators, the PEG of 1g be put into penicillin bottle postposition pressure cooker after high pressure sterilization about liquid
1ml, the PEG that 1ml is added in the inner prepare liquid up to 50% PEG)；
B. SP2/0 is collected in 50ml sterile centrifugation tube and counted (it is required that total number of cells are 1 × 106It is a), centrifugation 1300
Rev/min, totally 7 minutes；
C. sterilized petri dishes, sieve, penicillin bottle are got out, draws neck to put to death by four immune BLAB/c mouse, sets
It is impregnated 5 minutes in 75% alcohol；
D. SP2/0 murine myeloma cell is taken to mix with immune Balb/c Mouse spleen cells in the ratio of 1:5-1:10
Uniformly, 1300rpm is centrifuged 7 minutes, abandons supernatant, is tapped tube bottom with palm, is kept cell loosely uniform；
E. the preheating of 40 DEG C of metal baths is set, is added in 45s with 1mL suction pipe and is preheated to 40 DEG C of 1mL50%PEG4000, side
Edged gently vibrates；
F. 1640 incomplete culture mediums that 30mL is preheated to 37 DEG C are then added in 90s, are stored at room temperature 10 minutes；
G.1000rpm it is centrifuged 5 minutes, abandons supernatant, 1640 culture base weights of the 20mL containing 20% fetal calf serum and HAT are added
It is outstanding, it is dispensed on the culture plate of existing feeder cells, in 5% carbon dioxide incubator culture.
2.3.5 the selectivity culture of hybridoma
Fusion was initially added into selection culture solution after 24 hours, and detailed process is as follows:
A. it after merging 24 hours, is added in the complete 1640 culture medium of 20ml and is mixed with HAT 1.6ml and HT 0.4ml, be added
In 24 orifice plates, 500 holes μ l/；
B. liquid is changed after 5 days, after 1500 μ l are sucked out in hole every in 24 orifice plates, it is (every that the quasi- complete 1640 culture medium changed is added
The HT composition of the HAT and 0.6ml of 0.6ml is added in the complete 1640 culture medium of 60ml)；
C. liquid is changed after 7 days again, after 1500 μ l are sucked out in hole every in 24 orifice plates, the quasi- complete 1640 culture medium changed is added
(the HT composition of 1.2ml is added in the complete 1640 culture medium of every 60ml.).
After carrying out step c 3 to 7 days, the cell grown in the culture hole of cell colony in 24 orifice plates is collected, is carried out subsequent
Step.
2.3.6 the screening of hybridoma
By the hybrid tumor cell monoclonal obtained in 2.3.5 (monoclonal method refers to following 2.3.7), its training is taken
It supports supernatant and carries out following step:
A. be coated with: it is 2 μ g/ml that antibody, which is diluted to protein content, with the carbonate of 0.05M pH9.6 coating buffer.
Add 50 μ l in the reacting hole of each polystyrene board, 4 DEG C overnight.Next day discards solution in hole, is washed 3 times with washing buffer,
3 minutes every time (referred to as washing, similarly hereinafter).
B. it closes: adding skimmed milk power (BD company) PBS300 μ l containing 5% in the reacting hole of each polystyrene board, set
37 DEG C are incubated for 2 hours, are washed out.
C. it is loaded: adding certain diluted 50 μ l of measuring samples in the above-mentioned reacting hole being coated with, it is small to set 37 DEG C of incubations 1
When, it is washed out (while doing blank well, negative control hole and Positive control wells).
D. enzyme labeling antibody: in each reacting hole, the enzyme labelled antibody of diluted is added, and (by specification carries out dilute
Release) 50 μ l.37 DEG C are incubated for 1 hour, washing.
Plus substrate solution colour developing e.: be added the tmb substrate solution 50 μ l of Extemporaneous in each reacting hole, 37 DEG C 15 minutes.
F. it terminates reaction: 50 μ l of 2M sulfuric acid being added in each reacting hole.
G. result judgement: can be in the result that in white background, directly detects by an unaided eye: color be deeper in reacting hole, positive journey
Degree is stronger, and to be colourless or extremely shallow, the depth of the be in color of foundation is indicated negative reaction with "+", "-" number.It can also be examined in ELISA
It surveys on instrument in 450nm and 630 double UV check OD values, each hole OD value is surveyed after returning to zero with blank control wells, if more than defined yin
Property control 2.1 times of OD value, it is as positive.
H. positive hole is marked, the cell in positive hole is selected to carry out monoclonal.
I. result: supernatant is detected by microplate reader for the first time and obtains 18 plants of positive hybridoma cells altogether.By positive hybridoma
Carry out monoclonal by limiting dilution assay (see 2.3.7).
2.3.7 the monoclonal of hybridoma, expansion are cultivated and are frozen
The cloning of hybridoma is carried out using limiting dilution assay, and the specific method is as follows:
A. hybridoma adds after complete 1640 culture medium to 80ml is added in sterile centrifugation tube after taking fusion
The HT of 3.2ml is mixed, this suspension mixed is separately added into 96 hole cell wall panels, 100 holes μ l/, the lower right corner of every block of plate
Feeder cells suspension is not added for last three hole (H10, H11, H12) in case the plate added, is put into the dioxy of 37 DEG C, 5% by dilution use
Change carbon cell incubator；
B. will the cell in the hole of monoclonal suspend (with 200 μ l rifle featheriness) and count, by this cell suspension
It moves in the dilution holes H10 in the plate for having feeder cells, is put into the hole H11 from 20 μ l cell suspensions are taken out in the hole H10 with complete
1640 culture medium does 10 times of dilutions, then does 10 times of dilutions from taking out 20 μ l in the hole H11 and being put into the hole H12；
C. the cell suspension in the hole H12 is taken to be diluted to theoretically 1 cell/100 μ l with complete 1640 liquid, then this is dilute
It releases liquid and is respectively dropped into 96 orifice plates containing feeder cells suspension (a point drop is 48 holes after every hole dilution), every 100 μ l of hole；Set 37
DEG C, 5% carbon dioxide cell incubator culture；
D.1 monoclonal hole is marked after week, and the supernatant in monoclonal hole is detected with ELISA method (the same 2.3.2), choosing sun
Property hole in cell carry out cloning next time, obtain afterwards three times repeatedly can stably excreting monoclonal antibody 5 plants of hybridoma (into
All monoclonal holes of one plant of cell cloning next time of row cloning are the positive)；
E. result: being transferred to culture in 24 orifice plates (1 hole turns 1 hole) for the cell in monoclonal hole, after 3 days in 24 orifice plates point
At being divided into 4 holes behind 2 holes, then 3 days, then after 2 days the cell in this 4 hole is transferred to 50ml Tissue Culture Flask together and expands culture.Its
The middle strongest strain of hybridoma of the positive is named as F8-M-01.
F. hybridoma freezes: when 50ml culture bottle inner cell is paved with bottom of bottle area about 70% → will be in culture bottle
Cell blown and beaten with suction pipe, so that it is suspended completely, cell suspension moved into the centrifugation 1200 in 50ml sterile centrifugation tube and counting
Rev/min, 6 minutes → abandon supernatant, with cells frozen storing liquid (cells frozen storing liquid composition: 50% fetal calf serum；40% incomplete 1640 training
Nutrient solution；Precipitating 10%DMSO) is resuspended, adjusting cell density is 1 × 107/ L → is sub-packed in cryopreservation tube, 1ml/ branch → set -70 DEG C of ice
Case overnight → cell frozen is concealed in liquid nitrogen by next day.
2.3.8 the mass production of monoclonal antibody
By taking hybridoma cell strain F8-M-01 as an example, the Balb/c female mice of 10 8-10 week old is taken first to use atoleine
Pre-sensitization is only injected intraperitoneally in 0.3ml/, and hybridoma cell strain F8-M-01 is collected after 1 week with 1 × 106A/(same amount of normal saline
Be diluted to 1ml/ only) amount the mouse of above-mentioned pre-sensitization is injected intraperitoneally, observed after 10-14 days mouse abdominal distension obviously, be slow in action,
Ascites is collected when do not feel like eating and hair entanglement, neck is drawn to put to death mouse, is sucked ascites in centrifuge tube with clean dropper, centrifugation
2000 revs/min, 5 minutes.
As a result: being the positive through ELISA method detection ascites.
The identification of 2.4 monoclonal antibody subclass
Using mouse monoclonal antibody subclass parting kit (Thermo company), specific steps are referring to its specification.
As a result: through kit measurement, the monoclonal antibody hypotype of gained hybridoma cell strain F8-M-01 secretion is IgM.
2.5 immunoblottings (Western blotting)
2.5.1 sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
A. conventionally preparative separation glue and spacer gel；
B. take a certain amount of protein example and isometric 2 × SDS sample-loading buffer (100mmol/l Trisbase,
200mmol/l dithiothreitol (DTT), 4%SDS, 0.2 bromine Finland, 20%Glycerol) mixing, it is denaturalized 5 minutes in 100 DEG C；
C. it is loaded in discontinuous polyethylene acrylamide gel sample well according to every 100 μ g of swimming lane；
D. gel bottom edge is arrived at constant pressure 50V (spacer gel)/100V (separation gel) electrophoresis to bromophenol blue；
E. it takes out gel and is used for Western blotting.
2.5.2Western blotting
The transferred buffer of a.SDS-PAGE gel (25mmol/l Tris base, 192mmpl/l Dlycin, 20% first
Aldehyde) it impregnates 10-20 minutes；
B. tower is shifted according to the sequence assembled box type of 3 filter paper, gel, NC film, 3 filter paper, and it is faced south with NC film
The direction of pole is packed into transfer device；
C. under room temperature, current stabilization 0.8mA/cm2Electrotransfer, the time 90 minutes；
D. NC film is dyed with Ponceaux dye liquor, with marker pen labelled protein molecular weight standard amount, each band institute is in place
It sets, then Ponceaux is washed with deionized water；
E.NC film is closed 2 hours through 10% skimmed milk power in room temperature；
F. be diluted in 5% skimmed milk power antibody (freshly prepd monoclonal antibody 1:1000, anti-β-actin 1:5000) 4
DEG C be incubated overnight, TBST (10mmol/l Tris base, 150mmol/l NaCl, 0.05%Tween20, pH8.0), which shakes, to be washed 4 times
× 15 minutes；
G. the sheep anti-mouse igg marked with the HRP for being diluted in 4% skimmed milk power was in incubation at room temperature 4 hours；
H.TBST, which shakes, washes totally 4 times, 15 minutes/time；
I. A+B liquid in mixed in equal amounts ECL Color Appearance System, is added dropwise to NC film；
J. it is imaged.
K. result: being detected with the ascites that hybridoma F8-M-01 is generated through mouse peritoneal injection through WesternBlot method proves
The monoclonal antibody that the hybridoma cell strain generates can identify human blood coagulation factor VII I.
Claims (1)
1. a kind of hybridoma cell strain for secreting human blood coagulation factor VIII resisting monoclonal antibody, it is characterised in that: the hybridoma
Cell strain is to be named as F8-M-01, is preserved in China typical culture collection center on November 6th, 2015, deposit number is
The hybridoma cell strain of CCTCC C2015196, wherein the monoclonal antibody hypotype of hybridoma cell strain F8-M-01 secretion
For IgM.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510789803.4A CN105400769B (en) | 2015-11-17 | 2015-11-17 | The hybridoma cell strain of anticoagulin VIII monoclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510789803.4A CN105400769B (en) | 2015-11-17 | 2015-11-17 | The hybridoma cell strain of anticoagulin VIII monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105400769A CN105400769A (en) | 2016-03-16 |
| CN105400769B true CN105400769B (en) | 2019-04-12 |
Family
ID=55466530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510789803.4A Active CN105400769B (en) | 2015-11-17 | 2015-11-17 | The hybridoma cell strain of anticoagulin VIII monoclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105400769B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112094346B (en) * | 2020-06-01 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | Monoclonal antibody of mouse anti-cell single-chain transmembrane glycoprotein CD142 capable of being applied to tumor cell capture |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101906159A (en) * | 2010-06-21 | 2010-12-08 | 南京农业大学 | Hybridoma cell line D6D |
| CN101906160A (en) * | 2009-06-05 | 2010-12-08 | 苏州泽璟生物制药有限公司 | Human blood coagulation factor VIII resisting monoclonal antibody as well as preparation method and application thereof |
| CN102532316A (en) * | 2010-12-24 | 2012-07-04 | 神州细胞工程有限公司 | Anti-vWF (von Willebrand factor) monoclonal antibody and application thereof |
-
2015
- 2015-11-17 CN CN201510789803.4A patent/CN105400769B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101906160A (en) * | 2009-06-05 | 2010-12-08 | 苏州泽璟生物制药有限公司 | Human blood coagulation factor VIII resisting monoclonal antibody as well as preparation method and application thereof |
| CN101906159A (en) * | 2010-06-21 | 2010-12-08 | 南京农业大学 | Hybridoma cell line D6D |
| CN102532316A (en) * | 2010-12-24 | 2012-07-04 | 神州细胞工程有限公司 | Anti-vWF (von Willebrand factor) monoclonal antibody and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 凝血因子VIII抗体研究进展;周荣富等;《国外医学输血及血液学分册》;20061231;第26卷(第3期);第214-217页 * |
| 抗人凝血VIII因子的单克隆抗体制备及其鉴定;蒋亚林等;《复旦学报（自然科学版）》;19910331;第30卷(第1期);第62-69页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105400769A (en) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105801701B (en) | The heavy chain and light chain variable region of a kind of PCSK9 antibody and its application | |
| CN101793897A (en) | Method for improving screening efficiency of hybridoma | |
| CN105349496B (en) | The hybridoma cell strain of anti-macroglobulin monoclonal antibody | |
| CN101597334A (en) | Monoclonal antibody of bluetongue virus (BTV) and preparation method and application | |
| CN106589124B (en) | CD146 monoclonal antibody detects and separates the application in identification in glioma perivascular cell | |
| CN109320608A (en) | A kind of preparation method of hemoglobin antibodies | |
| CN105400769B (en) | The hybridoma cell strain of anticoagulin VIII monoclonal antibody | |
| CN105349495B (en) | The hybridoma cell strain of anticoagulin IX monoclonal antibody | |
| EP0142345A2 (en) | Anti-idiotypic vaccine employing anti-idiotypic monoclonal antibodies | |
| CN108642070B (en) | Recombinant human Fc antibody for specifically inducing tumor cell apoptosis and preparation method and application thereof | |
| CN105349497B (en) | Hybridoma cell strain of anti-alpha-antitrypsin polyclonal antibody | |
| CN105349524B (en) | The hybridoma cell strain of anticoagulin VII polyclonal antibody | |
| Chu et al. | A DNA‐based immunization protocol to produce monoclonal antibodies to blood group antigens | |
| CN101921336B (en) | Monoclonal antibody against human alpha1 acid glycoprotein and preparation method thereof | |
| CN107188961A (en) | A kind of aspergillus flavus resisting toxin M1 monoclonal antibodies and immunosorbent, immune affinity column and preparation method thereof | |
| CN104789535B (en) | Anti- methadone metabolin EDDP hybridoma cell strains and its preparation method and application | |
| De Ree et al. | Monoclonal antibodies raised against Pap fimbriae recognize minor component (s) involved in receptor binding | |
| CN101240021B (en) | Monoclonal antibody for anti-human CDK5RAP2 protein and application thereof | |
| CN107058240A (en) | One strain of hybridoma strain AB1 and its 2,4,5 trichlorophenoxyacetic acid monoclonal antibodies of generation | |
| Kudo et al. | Production of a human monoclonal antibody to a synthetic peptide by active in vivo immunization using a SCID mouse grafted with human lymphocytes | |
| EP0370090B1 (en) | Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens | |
| KLOCK et al. | Human hybridoma generation by hypo-osmolar electrofusion: characterization of human monoclonal antibodies to Schistosoma mansoni parasite antigens | |
| CN107083369A (en) | Anti-treeing Shrew CD3 molecule monoclonal antibodies and hybridoma cell strain and the application for secreting the antibody | |
| CN114316053B (en) | VCE monoclonal antibody and preparation method thereof | |
| CN102168071A (en) | Anti-melamine monoclonal antibody and kit for detecting melamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |